Milestone Pharma's Cardamyst Misses Revenue Targets

Milestone Pharmaceuticals stock plummeted after their first quarter earnings report, with a net loss of over twenty-six million dollars due to heavy spending on Cardamyst, their new nasal spray for PSVT. Despite bringing in $238,000 in sales, investors were disappointed as revenue and profit expectations were not met. The company has cash reserves to support further development and exploration of new uses for Cardamyst. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ee555358ae6e7a3c